NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular Injuries
Trial details
- Registry ID
- NCT04081103
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular InjuriesNCT04081103 | Glaukos Corporation | Phase 2 | Terminated | 2022-02-07Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |